Skip to content
Clinical Trials – home

M2m Med. Sp. z o.o.

Verified siteinfoFast reply

Poland Ul. Lwowska 34, 41-500 Chorzow, Poland

  • 9 trials recruiting
  • Crohn's disease · Dementia Alzheimer's type · Myelofibrosis
  • Adults and children

About Specializations

M2m Med. Sp. z o.o. in Chorzow, Poland specialises in clinical trials of conditions such as Crohn's disease, Dementia Alzheimer's type, Myelofibrosis, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Psychology – Behavior and Behavior Mechanisms

The site’s work centers on psychiatry and psychology with an emphasis on behavior mechanisms. Researchers are studying electronic cigarette cessation, evaluating whether cytisine combined with behavioral counseling can improve quit rates. The aim is to determine the effectiveness of this combined approach compared with placebo.

  • Cytisine pharmacotherapy for nicotine dependence
  • Structured behavioral counseling for vaping cessation
  • Combined treatment strategies for dual users of e‑cigarettes and tobacco cigarettes

Located in Chorzow, Poland, M2m Med. Sp. z o.o. operates as a commercial laboratory and has launched two investigator‑led trials with a team of eight researchers.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Lwowska 3441-500 ChorzowPoland
Recruiting now
9 trials
Conditions studied
29
Partner status
Verified site

More sites in ChorzowPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

23 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Loratadine
  • Sponsor:Pfizer Inc.

A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Myelofibrosis+3

Recruiting

Study of RVU120 treatment in patients with myelodysplastic syndrome, solid tumors, or acute myeloid leukemia who benefited from previous RVU120 therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

A study to test if tibulizumab works and is safe for adults with systemic sclerosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tibulizumab
  • Sponsor:Zura Bio Inc.

Crohn's disease

Recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Dementia Alzheimer's type

Not yet recruiting

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Immunisation+3

Not yet recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:Sanofi Pasteur Inc.

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.